LME-54
 | |
| Clinical data | |
|---|---|
| Other names | LME54; LME; Lysergic acid methylethylamide; LA-methylethylamide; N-Ethyl-N-methyllysergamide; N-Ethyl-N,6-dimethyl-9,10-didehydroergoline-8β-carboxamide |
| Routes of administration | Oral[1] |
| Drug class | Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C19H23N3O |
| Molar mass | 309.413 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
LME-54, or simply LME, also known as lysergic acid methylethylamide or as N-methyl-N-ethyllysergamide, is a serotonergic psychedelic of the lysergamide family related to lysergic acid diethylamide (LSD; LSD-25).[2][3][4][5][1] It is the analogue of LSD in which one of the N-ethyl groups has been replaced with an N-methyl group.[2][3][4]
The drug was tested in humans at a dose of 25 μg and was found to produce no effects at this dose in several subjects and to produce weaker effects than a 25 μg dose of LSD in one subject.[1] Higher doses do not appear to have been assessed.[1] Based on these findings, LME-54 has been described as weakly active or active but less so than LSD with no specific numbers available.[2][3][4][5][6][7] Its antiserotonergic activity in vitro does not appear to have been reported.[6]
LME-54 was first described in the scientific literature by Harold Alexander Abramson and Andre Rolo by 1965.[1][8]
See also
[edit]- Lysergic acid methylpropylamide (LMP-55)
- lysergic acid ethylpropylamide (LEP-57)
- Lysergic acid ethylamide (LAE-32)
References
[edit]- ^ a b c d e Abramson HA, Rolo A (September 1965). "Lysergic acid diethylamide (LSD-25). 38. Comparison with action of methysergide and psilocybin on test subjects". The Journal of Asthma Research. 3 (1): 81–96. doi:10.3109/02770906509106904. PMID 5318626.
- ^ a b c Shulgin AT (1976). "Psychotomimetic Agents". In Gordon M (ed.). Psychopharmacological Agents: Use, Misuse and Abuse. Medicinal Chemistry: A Series of Monographs. Vol. 4. Academic Press. pp. 59–146. doi:10.1016/b978-0-12-290559-9.50011-9. ISBN 978-0-12-290559-9.
- ^ a b c Shulgin AT (1980). "Hallucinogens". In Burger A, Wolf ME (eds.). Burger's Medicinal Chemistry. Vol. 3 (4 ed.). New York: Wiley. pp. 1109–1137. ISBN 978-0-471-01572-7. OCLC 219960627.
- ^ a b c Shulgin AT (1982). "Chemistry of Psychotomimetics". In Hoffmeister F, Stille G (eds.). Psychotropic Agents, Part III: Alcohol and Psychotomimetics, Psychotropic Effects of Central Acting Drugs. Handbook of Experimental Pharmacology. Vol. 55. Berlin: Springer Berlin Heidelberg. pp. 3–29. doi:10.1007/978-3-642-67770-0_1. ISBN 978-3-642-67772-4. OCLC 8130916.
- ^ a b Shulgin AT (2003). "Basic Pharmacology and Effects". In Laing RR (ed.). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137. ISBN 978-0-12-433951-4. Retrieved 1 February 2025.
- ^ a b Oberlender RA (May 1989). "Stereoselective aspects of hallucinogenic drug action and drug discrimination studies of entactogens". Purdue e-Pubs. Purdue University.
Table 2. Relative potency values for lysergic acid amides. [...]
- ^ Pfaff RC, Huang X, Marona-Lewicka D, Oberlender R, Nichols DE (1994). "Lysergamides revisited" (PDF). NIDA Research Monograph. 146: 52–73. PMID 8742794.
TABLE 2. Relative human potency of lysergic acid amides [...]
- ^ Abramson HA, Rolo A (1967). "Comparison of LSD with Methysergide and Psilocybin on Test Subjects" (PDF). In Abramson HA (ed.). The Use of LSD in Psychotherapy and Alcoholism: The Second International Conference on the Use of LSD in Psychotherapy and Alcoholism, May 8th–May 10th, 1965. Indianapolis: The Bobbs-Merill Company. pp. 53–73. OCLC 302168.
External links
[edit]
 | This hallucinogen-related article is a stub. You can help Wikipedia by expanding it. |